home / stock / sonn / sonn articles
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 8.5% to $1.18 Thursday morning on downward momentum. The...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow traded down 0.35% t...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 27.6% to $1.31 Wednesday morning after the company ...
U.S. stocks traded lower this morning, with the Nasdaq Composite falling 1.5% on Wednesday. Following the market opening Wednesday, the Dow traded ...
Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Li...
On Thursday, 369 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company in terms of market ca...
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares are trading lower by 24% to $0.21 Thursay afternoon after the company announced a ...
News, Short Squeeze, Breakout and More Instantly...
Sonnet BioTherapeutics Holdings Inc. Company Name:
SONN Stock Symbol:
NASDAQ Market:
PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that preclinical data and clinical trial design from the study of SON-080 (rec...
Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON‑080 was reviewed by the study's Data Safety Monitoring Board (DSMB) The adverse event profile and tolerability of SON-080 was consistent with data from previous IL-6 candidates, meeting the Phase...
PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lea...